Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05583526 · ClinicalTrials.gov registry record · Phase 3
A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 607
- Enrollment target
NCT05583526: Completed Phase 3 study, sponsored by Pfizer.
NCT05583526 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 607 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (21% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05583526, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 607 participants
- Enrollment target
Study Summary
A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents with Nonsegmental Vitiligo (Active and Stable) Tranquillo
Primary Outcome
Proportion of participants achieving F-VASI75 (defined as at least 75% improvement in F-VASI from Baseline) and T-VASI50 (defined as at least 50% improvement in T-VASI from Baseline)
Interventions
- DRUG Placebo
- DRUG Ritlecitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 607 participants |
| Start Date | 2022-12-01 |
| Est. Completion | 2026-02-05 |
| Phase | Phase 3 |
What the finished NCT05583526 record still lists
NCT05583526 is an interventional study that assigns participants to a tested intervention. The registered 607 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (21% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05583526 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05583526 about?
NCT05583526 is a clinical study titled "A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo". A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents with Nonsegmental Vitiligo (Active and Stable) Tranquillo
What is the current status of trial NCT05583526?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 607 participants. The study started on 2022-12-01. Estimated completion is 2026-02-05.
What interventions are being tested in trial NCT05583526?
The interventions under investigation include: Placebo (DRUG), Ritlecitinib (DRUG).
Who is sponsoring clinical trial NCT05583526?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05583526's enrollment target sits among peer trials
607 605th of 2000 higher than 1,395 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02064673 · 608 participants · Phase 3
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
- NCT06091202 · 608 participants · Phase 3
Tele-Collaborative Outreach to Rural Patients With Chronic Pain
- NCT06098144 · 608 participants · Phase 4
Smoking Cessation Program in the Construction Sector
- NCT02342444 · 606 participants · Phase 4
Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI